NLS Pharmaceutics Announces Pricing Of A Private Placement Offering Consisting Of The Issuance And Sale Of Up To 322,580 Common Shares Only At A Purchase Price Of $3.10 Per Common Share, For Aggregate Gross Proceeds Of Up To $1M

NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced the pricing of a private placement offering consisting of the issuance and sale of up to 322,580 common shares only, par value CHF 0.80 per share, at a purchase price of $3.10 per common share, for aggregate gross proceeds of up to $1.0 million, subject to shareholder approval. The initial closing of the offering in the amount of $500,000 is expected to occur on or before January 10, 2025, and the subsequent closing of $500,000 may occur, at the election of the purchaser, within 15 days following the Company meeting certain conditions, including the receipt of shareholder approval and the Company's common shares trading for at least ten consecutive trading days above the purchase price of $3.10 which corresponds to an approx. 15% premium.

The Company intends to use the net proceeds from the offering for general corporate purposes.